Literature DB >> 32842809

How do biosimilars sustain value, affordability, and access to oncology care?

Steven Simoens1.   

Abstract

Keywords:  Biosimilar; access; budget impact; oncology; value

Year:  2020        PMID： 32842809     DOI： 10.1080/14737167.2020.1813570

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis.

Authors:  Xinyi Xu; Shengzhao Zhang; Ting Xu; Mei Zhan; Chen Chen; Chenyu Zhang
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

2.  Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study.

Authors:  Steven Simoens; Arnold G Vulto; Pieter Dylst
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.